Background: Pulmonary pleomorphic carcinoma (PPC) is a rare tumor, and it usually has an aggressive clinical course and poor prognosis. We aim to analyze the clinicopathological features, management and prognostic factors of pulmonary pleomorphic carcinoma.
Patients And Methods: Using the surveillance, epidemiology, and end results (SEER) database, we identified 461 patients of pulmonary pleomorphic carcinoma from 2004 to 2014 including clinicopathological characteristics, treatment modalities and outcome data.
Results: The mean age of all PPC patients was 66 years and 58% of the patients were male. Most patients (80%) were white people, 53% were found in the right lung, and lesions were mostly observed in upper lobe (56%). The median overall survival was 9 months and overall 1-, 3- and 5-year survival rate was 45%, 29%, 23%. In Kaplan-Meier analysis, age, marital status, tumor primary site, gender, laterality, SEER summary stage, chemotherapy and surgery were associated with overall survival. Patients received surgery or chemotherapy had a better OS for patients with PPC. Multivariate Cox analysis revealed that SEER summary stage, age, surgery and chemotherapy were found to be independently associated with the OS. Surgery could significantly prolong survival in patients with localized stage and regional stage (HR = 0.120, 95% CI 0.038-0.383, p < 0.001; HR = 0.351, 95% CI 0.212-0.582, p < 0.001) while it did not have great impact on survival in patients with distant stage (p = 0.192). Chemotherapy decreased risk of death by 46% (HR = 0.544, 95% CI 0.393-0.752, p < 0.001) for patients with distant stage, whereas chemotherapy did not confer survival benefits to patients with localized stage and regional stage. But radiation did not have great impact on survival of patients with different stages in this study.
Conclusions: PPC mostly occurred in white people, with a median age of 66 years, and men were more susceptible to this disease. The SEER summary stage, age, surgery and chemotherapy were independently associated with prognosis. Surgery should be considered for the PPC patients with localized stage or regional stage, and chemotherapy should be recommended for the treatment of patients with distant stage.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969326 | PMC |
| http://dx.doi.org/10.1186/s12890-022-01915-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A review of submandibular gland extirpation in an Australian quaternary referral centre: aetiologies and trends over 35 years.
ANZ J Surg
December 2024
Department of Head and Neck Surgery, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
Background: Submandibular gland pathology is common but rarely reported. This study was performed to evaluate demographic, pathological, and survival outcomes associated with submandibular gland extirpation.
Methods: Retrospective analysis of patients treated in a single quaternary-care institution between 1989 and 2022 was performed.
Surgery for Classic, Pleomorphic and Non-classic Lobular Carcinoma In Situ: Surgery Rate, Risk of Upstaging and Short-Term Follow-Up.
Ann Surg Oncol
December 2024
Laboratory of Pathology Dordrecht, Dordrecht, The Netherlands.
Background: The Dutch breast cancer guideline recommends surveillance for classic lobular carcinoma in situ (LCIS), unless there is a discrepancy with mammographic findings, and surgery for pleomorphic and non-classic LCIS.
Objective: The aim of this study was to assess adherence to the guideline in daily practice, as well as the surgery rate, risk of upstaging, and events during follow-up.
Methods: Selection of patients from a nationwide cohort diagnosed between 2011 and 2020.
Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial.
EClinicalMedicine
January 2025
Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.
Background: Dual inhibition of cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed death ligand 1 (PD-L1) has been shown to be an effective treatment strategy in many cancers. We sought to determine the objective response rate of combination durvalumab (D) plus tremelimumab (TM) in parallel cohorts of patients with carefully selected rare cancer types in which these agents had not previously been evaluated in phase II trials and for which there was clinical or biological rationale for dual immune checkpoint inhibitor therapy to be active.
Methods: We designed a multi-centre, non-blinded, open-label phase II basket trial with each of the following 8 rare cancers considered a separate phase II trial: salivary carcinoma, carcinoma of unknown primary (CUP) with tumour infiltrating lymphocytes and/or expressing PD-L1, mucosal melanoma, acral melanoma, osteosarcoma, undifferentiated pleomorphic sarcoma, clear cell carcinoma of the ovary (CCCO) or squamous cell carcinoma of the anal canal (SCCA).
A 70-year-old man was referred to our hospital for an abnormal chest X-ray shadow. A chest CT scan showed a mass shadow with a cavitary lesion in segment 6 of the right lung. One year after radical resection(resection of the lower lobe of the right lung; pT2aN0M0, pStage ⅠB), the patient exhibited enlarged mediastinal lymph nodes and liver metastases, and postoperative recurrence was determined.
View Article and Find Full Text PDFPurpose: There is no current standard treatment regimen for carcinoma ex pleomorphic adenoma (CXPA) of the lacrimal gland. Neoadjuvant intraarterial cytoreductive chemotherapy (IACC) followed by multimodal therapy has achieved good locoregional control in adenoid cystic carcinoma of the lacrimal gland. We reviewed our experience with neoadjuvant IACC followed by multimodal therapy for CXPA of the lacrimal gland.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!